Biogen Gains Momentum After Breakout and Successful RetestBiogen Inc.BATS:BIIBfinvestnomicsBIIB is attracting buying interest following its breakout from a head and shoulders base formation and successful retest of the $190 support level. The stock’s ability to hold above breakout support suggests improving bullish momentum and renewed investor confidence. Biogen, Inc. is a $29.08 billion market cap biopharmaceutical company focused on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its portfolio includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS), SPINRAZA for spinal muscular atrophy (SMA), ADUHELM for Alzheimer’s disease, and FUMADERM for severe plaque psoriasis. BIIB is regarded as a wide economic moat company, supported by its strong intellectual property portfolio, specialized neuroscience expertise, and established position in neurological therapies. The company has delivered revenue and EPS growth in two of the last three quarters. Operating margin and net margin stand at 19% and 13%, respectively, while ROE and ROIC are 8% and 6%. In addition, Biogen maintains a strong balance sheet with a current ratio of 3.1x and a debt-to-equity ratio of 0.4x.